Showing 1861-1870 of 5631 results for "".
- iSTAR Medical’s Glaucoma Device MINIject Shows Positive One-Year Results in European Trialhttps://modernod.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/iSTAR Medical announced positive 1-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held November 13-15 2020. Po
- Safer and More Effective Glaucoma Surgical Options Will Drive Surgery Device Treatment Penetration Over Next Five Yearshttps://modernod.com/news/safer-and-more-effective-glaucoma-surgical-options-will-drive-surgery-device-treatment-penetration-over-next-five-years/2478181/Expanding use of surgical devices in patients with all stages of glaucoma will increase the role of surgery in the glaucoma treatment paradigm over the next 5 years, according to a Market Scope report. There are four FDA-approved minimally invasive glaucoma surgery (MIGS) stents in the US:
- EyePoint Pharmaceuticals Announces Addition of Dexycu and Yutiq to Department of Veteran Affairs Federal Supply Schedulehttps://modernod.com/news/eyepoint-pharmaceuticals-announces-addition-of-dexycu-and-yutiq-to-department-of-veteran-affairs-federal-supply-schedule/2477065/EyePoint Pharmaceuticals announced that it has signed an interim agreement with the U.S. Department of Veteran Affairs (VA) for Dexycu and Yutiq to be included on the Federal Supply Schedule (FSS), providing U.S. veterans and other federal government agencies with access to both products. The VA
- Second Sight Announces $2.4 Million, 4-Year Grant from NIH to Develop Spatial Localization and Mapping Technologyhttps://modernod.com/news/second-sight-announces-2-4-million-4-year-grant-from-nih-to-develop-spatial-localization-and-mapping-technology/2476926/Second Sight Medical Products announced receipt of a $2.4 million, 4-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is i
- Ivantis Announces 3-Year Results from FDA Clinical Trial Demonstrating Long-Term Reduction of Severe Major Surgeries for Glaucoma Patientshttps://modernod.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/Ivantis, developer of the Hydrus Microstent, announced the 3-year results from the HORIZON pivotal study. The 2-year results, which were the foundation of FDA approval, were presented in November 2017, and were recently published in the journal Ophthalmology.
- Statement From FDA Leadership On a Record Year for Device Innovationhttps://modernod.com/news/statement-from-fda-leadership-on-a-record-year-for-device-innovation/2479598/FDA Commissioner Scott Gottlieb, MD, and Jeff Shuren, MD, director for the Center for Devices and Radiological Health, released the following statement addressing a record year for device innovation: “The FDA’s focus on both safety and innovation stems from our historic mission
- EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019https://modernod.com/news/eyepoint-pharmaceuticals-to-launch-dexycu-and-yutiq-in-first-quarter-of-2019/2476226/During a corporate update, EyePoint Pharmaceuticals executives said they expect to launch both Dexycu (dexamethasone intraocular suspension 9%) and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) in the first quarter of calendar 2019. “EyePoint has made significant progress in
- Alcon’s Phaco Development (PD) Program Celebrates 10 Yearshttps://modernod.com/news/alcons-phaco-development-pd-program-celebrates-10-years/2476164/The Phaco Development (PD) program, an initiative between Alcon and specialist training institutes that builds cataract surgical capabilities across Asia and Russia, is celebrating its 10th anniversary this year. Over th
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety
- Novavax’s COVID-19 Vaccine Over 89% Effective in UK trial, Less So in South Africa Studyhttps://modernod.com/news/novavaxs-covid-19-vaccine-over-89-effective-in-uk-trial-less-so-in-south-africa-study/2478809/Novavax shares gained as much as 26% on Thursday after the company said its protein-based COVID-19 vaccine candidate NVX-CoV2373 met the primary endpoint of a phase 3 trial in the UK, demonstrating an efficacy rate of over 89%, with high protection also seen against the fast-spreading UK variant.